Trial reportJournal of neurology2018
Positive effects of fampridine on cognition, fatigue and depression in patients with multiple sclerosis over 2 years.
Trial report in Journal of neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06064162 (A Pilot Study of Intravenous, Subanesthetic Dose of Ketamine Versus Placebo, A Crossover Design, for Multiple Sclerosis Related Fatigue), which is not on this map. Cited by 28 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pilot Study of Intravenous, Subanesthetic Dose of Ketamine Versus Placebo, A Crossover Design, for Multiple Sclerosis Related Fatigue
Who cites it
28 citing papers in PubMed, 4 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- The effects of fampridine on MS-related fatigue: a systematic review.Frontiers in neurology · 2025Pooled it
- Fampridine for gait imbalance in patients with multiple sclerosis (MS): a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Pooled it
- Cognitive Efficacy of Pharmacologic Treatments in Multiple Sclerosis: A Systematic Review.CNS drugs · 2020Pooled it
- Effects of Fampridine in People with Multiple Sclerosis: A Systematic Review and Meta-analysis.CNS drugs · 2019Pooled it
- The effect of fampridine on working memory: a randomized controlled trial based on a genome-guided repurposing approach.Molecular psychiatry · 2025Trial
- Trial
- 4-aminopyridine exerts anxiolytic and pro-cognitive effects in mice model of medial prefrontal cortex ischemia.Metabolic brain disease · 2025Article
- Sleep Deprivation-Induced Anxiety Alleviated by Oral Administration of 4-Aminopyridine in Male Mice.Brain and behavior · 2025Article
- Real-World Experience of Sustained-Release Fampridine in Chinese Patients With Multiple Sclerosis: A Case Series on Walking Impairment and Fatigue.Behavioural neurology · 2025Article
- Effect of Fampridine on cognition in patients with multiple sclerosis (MS): a systematic review and meta-analysis.Caspian journal of internal medicine · 2025Review
- Investigating the Safety of Fampridine in Patients with Different Stages of Multiple Sclerosis.International journal of preventive medicine · 2025Article
- Article
- Overview of the Current Pathophysiology of Fatigue in Multiple Sclerosis, Its Diagnosis and Treatment Options - Review Article.Neuropsychiatric disease and treatment · 2023Review
- Subsecond Three-Dimensional Nitrogen-15 Magnetic Resonance Imaging Facilitated by Parahydrogen-Based Hyperpolarization.The journal of physical chemistry letters · 2022Article
- The effectiveness of amantadine and dalfampridine in improving fatigue in patients with multiple sclerosis: A randomized, double-blind, clinical trial.Current journal of neurology · 2022Article
- The longitudinal relationship between fatigue, depression, anxiety, disability, and adherence with cognitive status in patients with early multiple sclerosis treated with interferon beta-1a.eNeurologicalSci · 2022Article
- Symptom Interconnectivity in Multiple Sclerosis: A Narrative Review of Potential Underlying Biological Disease Processes.Neurology and therapy · 2022Review
- Efficacy of prolonged-release fampridineTherapeutic advances in neurological disorders · 2022Article
- Multiple sclerosis-related fatigue lacks a unified definition: A narrative review.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2022Review
- Prolonged-release fampridine for the treatment of myoclonus after cervical myelitis: a case report.Therapeutic advances in neurological disorders · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the effects of PR-fampridine on cognitive functioning, fatigue and depression in patients with multiple sclerosis (PwMS).
methodsThirty-two PwMS were included in this trial. Cognitive performance was assessed in an open-label and randomized double-blind, placebo-controlled study design using a comprehensive neuropsychological test battery as well as questionnaires examining depression and fatigue.
resultsWe found significant improvements in cognitive measures assessing alertness (tonic alertness, p = 0.0244 and phasic alertness, p = 0.0428), psychomotor speed (p = 0.0140) as well as verbal fluency (p = 0.0002) during open-label treatment with PR-fampridine. These effects of performance were paralleled by patients' perception of reduced fatigue (physical, p = 0.0131; cognitive, p = 0.0225; total, p = 0.0126). Fampridine-induced improvements in phasic alertness (p = 0.0010) and measures of fatigue (physical, p = 0.0014; cognitive, p = 0.0003; total, p = 0.0005) were confirmed during randomized, double-blind, placebo-controlled assessment in the second year. In addition, we found positive effects of PR-fampridine on depressive symptoms (p = 0.0049). We demonstrated persisting beneficial effects of PR-fampridine on fatigue in PwMS over a period of more than 2 years. Drug responsiveness regarding cognitive performance and fatigue was not limited to walking responders.
conclusionsOur data demonstrate significant positive effects of treatment with PR-fampridine over 2 years on different cognitive domains as well as fatigue and depression in a cohort of PwMS. These findings imply that PR-fampridine should be considered as symptomatic treatment improving aspects of cognition, fatigue and depression in PwMS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.